Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195973 · ClinicalTrials.gov registry record · Phase 1
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02195973 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 15 participants.
The verdict
NCT02195973, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial effects when combined with paclitaxel in women with platinum resistant ovarian cancer. Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone chemotherapy inclusive of a platinum compound (e.g. carboplatin or cisplatin).
Interventions
- DRUG LDE225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195973
The ClinicalTrials.gov registry entry for NCT02195973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LDE225 is the first listed.
NCT02195973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195973 about?
NCT02195973 is a clinical study titled "Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer". The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial effects when combined with paclitaxel in women with platinum resistant ovarian cancer. Platinum resistant ovarian cancer refers to recurrent ovarian cancer that has undergone chemotherapy inclusive of a platin...
What is the current status of trial NCT02195973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-09. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT02195973?
The interventions under investigation include: LDE225 (DRUG).
Who is sponsoring clinical trial NCT02195973?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.